Key Takeaways
-
Scientists discovered that an FDA-approved epilepsy medication can both relieve joint pain and reverse cartilage damage in osteoarthritis.
-
The drug targets a specific protein, Nav1.7, which is responsible for both transmitting pain signals and driving cartilage destruction.
-
Delivered via a temperature-sensitive hydrogel, the treatment provides localized, long-lasting healing over several weeks without systemic side effects.
A dual-action breakthrough for joint health
For millions of people suffering from osteoarthritis, daily life can be a painful struggle against stiffness and joint degradation. Current treatments, ranging from over-the-counter painkillers to steroid injections, typically offer only temporary relief and fail to halt the underlying structural damage. However, a promising new therapeutic approach could soon change how this common condition is treated.
Researchers have discovered that lacosamide, an FDA-approved medication traditionally used to treat epilepsy, can offer significant relief for osteoarthritis while actively helping damaged cartilage repair itself. The drug works by blocking a protein known as Nav1.7. While Nav1.7 was previously thought to operate primarily in nerve cells to transmit pain signals, scientists found that it is also highly active in cartilage-maintaining cells during osteoarthritis flare-ups. By inhibiting this specific protein, lacosamide not only quiets pain nerves but also stops cartilage breakdown and encourages beneficial tissue repair.
To maximize the drug’s effectiveness and avoid the unwanted systemic side effects of oral medications, the research team developed an innovative delivery method. They combined the epilepsy drug with a specialized, temperature-sensitive hydrogel made from Collagen II. The material remains liquid inside a cool syringe but transforms into a firm, supportive jelly once it reaches body temperature inside the joint.
This clever gel acts as a localized reservoir, holding the medication exactly where it is needed and slowly releasing it over the course of a month. In preclinical testing, a single injection of this hydrogel every four weeks prevented cartilage loss far more effectively than a daily oral pill.
Because lacosamide is already FDA-approved for human use, this innovative approach could advance to clinical trials much faster than a brand-new drug. By focusing on true disease modification rather than mere symptom management, researchers are paving the way for a future where osteoarthritis patients can enjoy lasting protection, healthier joints, and pain relief without relying on addictive opioids.
